Stryker Earnings Call Transcripts
Fiscal Year 2025
-
Delivered double-digit organic sales and EPS growth in 2025, driven by strong U.S. and international performance, robust product launches, and margin expansion. 2026 guidance anticipates 8%-9.5% organic sales growth and continued margin strength despite tariff headwinds.
-
The event outlined a refreshed strategy emphasizing digital solutions, operational excellence, and continued M&A in high-growth adjacencies. Guidance includes 150 bps margin expansion over three years, double-digit EPS growth, and a focus on smart hospital platforms and global expansion.
-
Delivered 9.5% organic sales growth and 11.1% adjusted EPS growth year-over-year, with strong U.S. and international performance across all segments. Raised full-year guidance, citing robust demand, margin expansion, and successful integration of recent acquisitions.
-
MedSurg and Neurotechnology continue to deliver double-digit organic growth, driven by innovation, targeted M&A, and strong execution across diverse business units. New product launches, digital integration, and expansion in areas like peripheral vascular and robotics are expected to sustain outperformance.
-
Delivered 10.2% organic sales growth and 11.4% adjusted EPS growth year-over-year, driven by robust demand across MedSurg, Neurotechnology, and Orthopaedics. Raised 2025 guidance, citing strong operational momentum, successful product launches, and effective tariff mitigation.
-
Leadership transition is seamless, with a continued focus on top-line growth, profitability, and M&A. Strong Q1 results, robust product pipeline, and effective tariff mitigation support ongoing margin expansion. Multi-year innovation cycles and recent acquisitions are expected to sustain growth.
-
The meeting confirmed strong sales growth, successful acquisitions, and robust innovation pipelines, with all management proposals and director nominees approved. Leadership transitions and digital healthcare initiatives were highlighted, and shareholder engagement addressed compensation and technology strategy.
-
Q1 2025 delivered 10.1% organic sales growth and 13.6% adjusted EPS growth, led by strong U.S. and international performance, robust product launches, and successful integration of Inari Medical. Full-year guidance was raised, with tariff impacts expected to be mitigated by sales momentum and operational efficiencies.
-
Leadership outlined a strategy of portfolio optimization, innovation, and operational efficiency, targeting 8%-9% growth and margin expansion in 2025. Growth is driven by ASC and robotics adoption, new product launches, and targeted M&A, with ongoing international expansion and digital integration.
Fiscal Year 2024
-
Organic sales and EPS grew double digits in Q4 and 2024, with strong performance across all segments and robust product launches. 2025 guidance calls for 8%-9% organic sales growth and continued margin expansion, with the Inari acquisition and spine divestiture shaping the portfolio.
-
Q3 2024 saw 11.5% organic sales growth and 16.7% higher adjusted EPS, driven by double-digit gains across MedSurg, Neurotechnology, and Orthopaedics. Full-year guidance was raised to 9.5%-10% organic sales growth and $12.00-$12.10 EPS, with strong momentum from innovation, M&A, and robust procedure volumes.
-
Strong first-half growth in orthopedics was driven by Mako and new product launches, with pricing pressure easing and share-taking strategies in place. Mako Spine and Shoulder are set for launch, while Pangea is expected to boost trauma growth in 2025. Robust capital spending and ASC demand support continued momentum.
-
Q2 2024 saw 9% organic sales growth, 10.6% higher adjusted EPS, and record Mako installations, with strong U.S. and international performance. Guidance for 2024 was raised, driven by robust demand, new product launches, and a healthy capital backlog.